Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pacira Pharm Inc (NQ: PCRX )

14.35 +0.86 (+6.34%)
Official Closing Price Updated: 4:15 PM EDT, Sep 17, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Pacira Pharm Inc

< Previous 1 2 Next >
Pacira BioSciences Announces Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Second Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Second Quarter 2023 Financial Results on Wednesday August 2, 2023
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2023 Jefferies Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports First Quarter 2023 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report First Quarter 2023 Financial Results on Wednesday May 3, 2023
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Partners with The Invited Celebrity Classic – a PGA TOUR Champions Event – to Make iovera° The Official Non-Opioid Pain Management Partner
PGA TOUR Champions Golfer, Paul Goydos, Promotes Further Awareness of Non-Opioids with 2023 Partnership 
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences, Inc. Appoints Christopher Young as Chief Manufacturing Officer
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces Repayment and Termination of Term Loan B Facility Using Proceeds from New $150 Million 5-Year Term Loan A Facility and Existing Cash Resources
From Pacira BioSciences
Via GlobeNewswire
Pacira Announces FDA Acceptance of sNDA for Exparel Nerve Blocks to Produce Regional Analgesia in Lower Extremity Procedures
From Pacira BioSciences
Via GlobeNewswire
Third Circuit Court Upholds Decision to Dismiss Pacira BioSciences, Inc. Lawsuit
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Announces Yvonne Greenstreet to Retire from Board of Directors
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Participate in Fireside Chat at the 2023 Barclays Global Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Full-Year and Fourth Quarter 2022 Financial Results
From Pacira BioSciences
Via GlobeNewswire
LPGA, Pacira BioSciences Partner to Raise Awareness of Non-Opioid Pain Management Solutions
Multi-year agreement will make Pacira’s medical device ioveraº the Official Non-Opioid Pain Management Partner of the LPGA 
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report 2022 Financial Results on Tuesday February 28, 2023
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Preliminary Unaudited Total Revenue for 2022 of $666.8 Million
EXPAREL average daily sales 104% of the prior year for the fourth quarter and 107% of the prior year for the month of December 
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Preliminary Net Product Sales of $57.5 Million for November 2022
EXPAREL sales were 99 percent and unit volumes were 104 percent of November 2021 
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Preliminary Net Product Sales of $54.9 Million for October 2022
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences to Present at Two Healthcare Conferences in November
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Third Quarter 2022 Financial Results
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Third Quarter 2022 Financial Results on Thursday November 3, 2022
From Pacira BioSciences
Via GlobeNewswire
Pacira BioSciences Reports Preliminary Third Quarter 2022 Revenue of $167.5 Million
-- EXPAREL average daily sales 109% of the prior year for the third quarter and 113% of the prior year for the month of September -- 
From Pacira BioSciences
Via GlobeNewswire
Pacira to Report Second Quarter 2022 Financial Results on Wednesday August 3, 2022
From Pacira BioSciences
Via GlobeNewswire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.